Abstract Objectives To explore the long-term efficacy and possible mechanism of endolymphatic sac decompression (ESD) in the treatment of Meniere’s disease(MD) by electrocochleography. Design Prospective cohort study. Setting “Blinded for review” Participants A total of 85 patients with MD who underwent unilateral ESD between June 2015 and November 2019 at“Blinded for review”were enrolled. Main outcome measures The Dizziness Handicap Inventory (DHI), Tinnitus Handicap Inventory (THI), pure tone audiometry, and electrocochleography were used for assessment. The mean follow-up time was 26 months (range: 7–60 months). Results The number of vertigo episodes was significantly reduced following ESD compared to before the surgery (P<0.005), and all patients achieved complete or basic control of vertigo as evidenced by a decrease in DHI score (P<0.005). THI scores of patients with tinnitus were also lower after as compared to before ESD (P<0.005), whereas no significant change in average hearing threshold of the affected side was observed (P>0.05). The cochlear summating potential (SP)/auditory nerve action potential (AP) area ratio in the electrocochleogram of the affected side was negatively correlated with DHI score (rs=−0.159, P=0.0074). Conclusions ESD achieved effective long-term control of vertigo in MD patients and improved the associated tinnitus without any obvious damage to hearing. Electrocochleography was useful for postoperative monitoring; the SP/AP area ratio of the affected side was closely related to the improvement of postoperative vertigo, possibly reflecting greater relief of pressure in the endolymphatic sac. Keypoints •ESD provided long-term control of vertigo in MD patients and improved the accompanying tinnitus without obviously damaging hearing. •ECochG is useful for monitoring the postoperative outcome of ESD. •The SP/AP area ratio of the affected side was closely related to the improvement of postoperative vertigo. •The endolymphatic sac is a “decompression reservoir” of the membranous labyrinth. •ESD may provide space for expansion of the endolymphatic sac and relieve pressure within the membranous labyrinth caused by endolymphatic hydrops, thereby reducing the risk of sac rupture and restoring pressure balance to reduce the sensation of vertigo.

Objectives: Sudden sensorineural hearing loss (SSNHL) is an emergency disease with undefined pathogenesis in the otolaryngology department. In our previous study, we found patients with SSNHL had lower serum concentration of Matrix metalloprotease 9 (MMP-9) than healthy controls, and the result was accordant with auto-immune diseases. This study aimed to reveal the correlation between changes in serum MMP-9 concentration following treatment with the outcomes of patients and to provide further evidence that immune disorder was the main pathogenesis of SSNHL. Design, setting, and participants: Fifty-two patients with SSNHL, hospitalized in The First Affiliated Hospital of Chongqing Medical University from March 2019 to August 2019, were enrolled. The serum concentration of MMP-9 was detected by enzyme-linked immunosorbent assay (ELISA). Main outcome measure: The mean concentration of MMP-9 before treatment was compared with the post-treatment concentration by the Mann-Whitney U test. The correlations between favorable outcomes of patients and clinical characteristics were measured with the Chi-squared test and binary multiple logistic regression analysis. Results: In treatment responders, mean serum concentration was elevated from 106.85±41.40ng/ml to 144.03±37.65 ng/ml following treatment (P＜0.001), while in non-responders it decreased from 132.09±59.21 ng/ml to 106.82±49.93 ng/ml (P=0.142). Changes in MMP-9 concentration was the only factor associated with favorable outcomes (P=0.008, OR=5.13, 95% CI: 1.53-17.28). Conclusions: Elevated MMP-9 concentration is a potential prognosis biomarker in patients with SSNHL. These findings are in line with auto-immune diseases and indicate immune disorder is mainly pathogenesis in SSNHL. Keywords Sudden sensorineural hearing loss; Matrix metalloprotease 9; Immune disorder; prognosis; Enzyme-linked immunosorbent assay